30
Participants
Start Date
March 23, 2020
Primary Completion Date
January 8, 2021
Study Completion Date
February 16, 2021
75 mg linzagolix tablet
For oral administration once daily
200 mg linzagolix tablet
For oral administration once daily
Add-back capsule (E2 1 mg / NETA 0.5 mg)
For oral administration once daily
Placebo tablet to match 75 mg linzagolix tablet
For oral administration once daily
Placebo tablet to match 200 mg linzagolix tablet
For oral administration once daily
Placebo capsule to match Add-back capsule
For oral administration once daily
A Premier Medical Research of Florida, LLC / ID # 752, Orange City
Clinical Associates of Orlando, LLC / ID # 779, Orlando
Coral Way Research / ID # 799, Miami
La Salud Research Clinic, Inc. / ID # 824, Miami
Dr. David I. Lubetkin, LLC / ID # 703, Boca Raton
Clinical Research Associates Inc / ID # 802, Nashville
ClinOhio Res Services, LLC / ID # 722, Columbus
Complete Healthcare for Women / ID # 801, Columbus
Hilltop OBGYN / ID # 711, Franklin
Onyx Clinical Research / ID # 793, Flint
Valley OBGYN / ID # 704, Saginaw
Providea Health Partners LLC / ID # 734, Evergreen Park
Applied Res Center of Ar / Id # 735, Little Rock
HCWC dba DiscoveryClinical Trials / ID # 771, Dallas
Signature Gyn Services / ID # 726, Fort Worth
Medical Colleagues of Texas / ID # 819, Katy
Maximos OB/GYN, League City
Austin Area ObGyn PLLC / ID # 701, Austin
OB/GYN North Austin / ID # 764, Austin
Adv Womens Health Institute / ID # 761, Greenwood Village
Red Rocks OB/GYN / ID # 732, Lakewood
Physicians Research Options / ID # 766, Draper
Futura Research, Inc. / ID # 781, Norwalk
CARe Clinic / ID # 872, Red Deer
Puerto Rico Medical Res Inc. / ID # 890, Ponce
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
INDUSTRY